ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: ,124 In 2010, Zhao et al125 observed that in the absence of BCR-ABL drug resistance mutations, HIF-1α can stimulate higher levels of BCR-ABL expression in CML cell lines, leading to leukemic cells exhibiting enhanced resistance to IM.